Why the study?
Prevention and treatment of many cardiovascular diseases remain limited, driving a need for more effective and safer pharmacological strategies.
Design
Review
No takes yet. Share an insight, caveat, or question.
Clinicians should integrate novel therapies and safety withdrawals into practice; extends consolidated evidence for CV pharmacotherapy research.
Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results which did not confirm the primary endpoints and the withdrawal from the U.S. market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing phase 2 and 3 clinical trials.
Tamargo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: